Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
CHICAGO, Aug. 03, 2017 -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and integrating molecular and clinical data, and the University of Virginia Cancer Center are collaborating on a new initiative aimed at helping researchers identify more effective care for patients diagnosed with large granular lymphocyte leukemia (LGL leukemia), a rare form of blood cancer.
After conducting a rigorous review and selection process, the University of Virginia Cancer Center selected Tempus to provide genomic sequencing and analytics for patients in its LGL Leukemia Registry. The goal is to identify personalized treatment opportunities based on genomic signatures and to create a genomic data repository to help fuel future exploratory scientific research and development.
“We are pleased to launch this collaboration with UVA Cancer Center, which will allow the creation of the most comprehensive genomic and clinical data set for LGL leukemia,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “With an analyzed data set of this size, we hope to assist researchers working to accelerate discovery and help patients.”
“At the UVA Cancer Center we are committed to delivering the most effective treatment for our patients possible,” said Thomas P. Loughran Jr., Director of the UVA Cancer Center and the physician responsible for discovering LGL leukemia. “Our goal in partnering with Tempus is to provide our researchers more information about patients afflicted with LGL leukemia, giving them insight into additional potential avenues for research and treatment.”
UVA Cancer Center is one of 69 National Cancer Institute (NCI)-designated cancer centers and the only cancer center in Virginia nationally ranked by U.S. News & World Report for 2016-2017.
About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and visit us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.
Clo Ewing Director of Communications at Tempus [email protected]
